MedTrace Logo

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

NCT07428044 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

Conditions

  • Non-Small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage II
  • Non-Small Cell Lung Cancer Stage IIIA
  • Non-Small Cell Lung Cancer Stage IIIB

Interventions

DRUG

Trastuzumab Deruxtecan

Trastuzumab deruxtecan (T-DXd, fam-trastuzumab deruxtecan-nxki) is a novel HER2- targeting antibody-drug conjugate (ADC).

Sponsors & Collaborators

Principal Investigators

  • James Isbell, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-13
Primary Completion
2027-02-13
Completion
2027-02-13
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07428044 on ClinicalTrials.gov